Table 3 (abstract O10). Treatment regimens and adverse outcome in the childhood TA cohort
From: Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one
Induction therapy | No. of patients (Total N = 27) | Median PVAS at diagnosis (range) | Inactive disease at 6 months | Therapy for maintenance of remission/ during disease course | No. of patients with flares | Death | Inactive disease at last follow up |
|---|---|---|---|---|---|---|---|
CS only | 4 (15) | 16 (8–17) | 1/3 | CS, Cyclo, Aza, MMF, MTX | 3/4 | 1/4 | 1/3 |
CS + MTX | 10 (37) | 15.5 (6–21) | 2/10 | CS, Cyclo, Aza, Lef, MTX, Biologics | 7/10 | 0/10 | 5/10 |
CS + Cyclo | 5 (19) | 7 (6–35) | 2/4 | CS, Cyclo, Aza, Lef, MTX, Biologic | 3/5 | 1/5 | 3/4 |
CS + MTX + Biologic | 3 (11) | 10 (6–25) | 3/3 | CS, Biologic + Lef/MTX | 0/3 | 0/3 | 3/3 |
No treatment | 5 (19) | 10 (6–17) | 5/5 | None | 0/5 | 0/5 | 5/5 |